Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer

Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks

Date

20 Oct 2023

Session

Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer

Topics

Targeted Therapy;  Basic Science

Tumour Site

Small Cell Lung Cancer;  Neuroendocrine Neoplasms;  Non-Small Cell Lung Cancer;  Sarcoma

Presenters

All Speakers

Authors

C.M. Rudin1, P. Schoeffski2, Z. Piotrowska3, A. Speakers4

Author affiliations

  • 1 Thoracic Oncology, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 KU Leuven - Laboratory of Experimental Oncology, 3000 - Leuven/BE
  • 3 Hematology/oncology Dept., MGH - Massachusetts General Hospital, 02114 - Boston/US
  • 4 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction of Agenda and Speakers

Presenter: Charles Rudin

Session: Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.